Century Therapeutics, Inc. Deferred Revenue
Century Therapeutics, Inc. (IPSC) had Deferred Revenue of $109.16 million as of 2024-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2025-03-19
- 2024-12-31: Deferred Revenue $109.16M.
- 2024-09-30: Deferred Revenue $113.34M.
- 2024-06-30: Deferred Revenue $114.13M.
- 2024-03-31: Deferred Revenue $114.90M.
| Period end | Deferred Revenue |
|---|---|
| 2024-12-31 | $109.16M 10-K · filed 2025-03-19 |
| 2024-09-30 | $113.34M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $114.13M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $114.90M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $115.75M 10-Q · filed 2024-11-05 |
| 2023-09-30 | $116.02M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $116.17M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $116.27M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $117.99M 10-Q · filed 2023-11-09 |
| 2022-09-30 | $118.51M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $120.73M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $122.13M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |